Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer

Xi, Mian; Yang, Yingjie; Zhang, Li; Yang, Hong; Merrell, Kenneth W.; Hallemeier, Christopher L.; Shen, Robert; Haddock, Michael G.; Hofstetter, Wayne L.; Maru, Dipen M.; Ho, Linus; Wu, Carol C.; Liu, Mengzhong; Lin, Steven H.

doi:10.1097/sla.0000000000002670

Cited by 72 publications

(63 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 However, the clinical outcome of patients with EC who do not achieve a pCR remains poor, with a recurrence rate as high as >50%. [6][7][8] Therefore, searching for new strategies to improve pCR rate after neoadjuvant CRT AND to reduce the risk of recurrence in high-risk patients is essential.…”

Section: Introductionmentioning

confidence: 99%

Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma

Zhou

Yang²,

Zhang

et al. 2020

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

We aimed to evaluate the changes in indoleamine 2,3dioxygenase 1 (IDO1) expression, programmed cell death-ligand 1 expression, and CD8 density after neoadjuvant chemoradiation therapy (CRT) and prognostic significance in 138 patients with esophageal squamous cell carcinoma. Both pre-CRT biopsies and post-CRT surgical specimens were available in 82 patients. IDO1 and programmed cell Purpose: Despite good preclinical evidence, clinical data on the effect of neoadjuvant chemoradiation therapy (CRT) on expression of immune markers in esophageal cancer are limited. This study aimed to evaluate the changes in indoleamine 2,3-dioxygenase 1 (IDO1) expression, programmed cell death-ligand 1 (PD-L1) expression, and CD8þ tumor-infiltrating lymphocyte status after neoadjuvant CRT and the prognostic significance in esophageal squamous cell carcinoma (ESCC). Methods and Materials: Between 2003 and 2017, 138 patients with ESCC who underwent neoadjuvant CRT and esophagectomy without achieving pathologic complete response were included for analysis. Both pre-CRT biopsies and post-CRT surgical specimens were available in 82 patients. Immunohistochemistry of IDO1, PD-L1, and CD8 density were analyzed. Results: Among 82 paired samples, the expression levels of IDO1 and PD-L1 and CD8 density increased significantly after neoadjuvant CRT (P < .01 for all). Patients with high IDO1 expression after CRT had poorer overall survival (P Z .001) and recurrence-free survival (P < .001) than those with low IDO1 expression. High post-CRT CD8 density was significantly correlated with more favorable overall

show abstract

Section: Introductionmentioning

confidence: 99%

Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma

Zhou

Yang²,

Zhang

et al. 2020

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Serous epithelial ovarian carcinoma has a very low five-year survival rate of 42% for stage III and 26% for stage IV [7] with a 19% recurrence rate [8]. Esophageal adenocarcinoma represents a similarly low five-year survival rate of 33% to 44% [9], depending on the treatment used, and can result in a recurrence rate as high as 43.2% [10].…”

Section: Introductionmentioning

confidence: 99%

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

Rowe¹,

Cheng²,

Ly³

et al. 2018

Plasma

View full text Add to dashboard Cite

Abstract:To determine appropriate treatment doses of cold atmospheric plasma (CAP), the Canady Helios Cold Plasma Scalpel was tested across numerous cancer cell types including renal adenocarcinoma, colorectal carcinoma, pancreatic adenocarcinoma, ovarian adenocarcinoma, and esophageal adenocarcinoma. Various CAP doses were tested consisting of both high (3 L/min) and low (1 L/min) helium flow rates, several power settings, and a range of treatment times up to 5 min. The impact of cold plasma on the reduction of viability was consistently dose-dependent; however, the anti-cancer capability varied significantly between cell lines. While the lowest effective dose varied from cell line to cell line, in each case an 80-99% reduction in viability was achievable 48 h after CAP treatment. Therefore, it is critical to select the appropriate CAP dose necessary for treating a specific cancer cell type.

show abstract

“…In consideration of the low data availability, only few studies dealt with the long-term follow-up after resected EC up till now. These reports usually evaluated staging, the treatment modalities, and the different pattern of postoperative tumor recurrence, respectively [13,14,[17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Hazard Curves for Tumor Recurrence and Tumor-Related Death Following Esophagectomy for Esophageal Cancer

Lindenmann

Fediuk

Fink-Neuboeck

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: The knowledge of both patterns and risk of relapse following resection for esophageal cancer is crucial for establishing appropriate surveillance schedules. The aim of this study was to evaluate the pattern of hazards for tumor recurrence and tumor-related death in the postoperative long-term follow-up after esophagectomy. Methods: Retrospective single-center analysis of 362 patients, with resected esophageal cancer. Multivariate Cox proportional hazard model was used. Results: A total of 192 (53%) had postoperative tumor recurrence. The relapse patterns of adenocarcinoma and squamous-cell carcinoma showed that each had a single peak, 12 months after surgery. After induction there was one peak at 5 months, the non-induced patients peaked 11 months, postoperatively. At 18 months, the recurrence hazard declined sharply in all cases. The hazard curves for tumor-related death were bimodal for adenocarcinoma, with two peaks at 6 and 22 months and one single peak for squamous-cell carcinoma at 18 months after surgery, showing pronounced decline later on. Conclusion: In curatively resected esophageal cancer, both tumor recurrence hazard and hazard for tumor-related death showed distinct, partly bimodal patterns. It could be justified to intensify the surveillance during the first two postoperative years by initiating a close-meshed follow-up to detect and treat tumor recurrence, as early as possible.

show abstract

Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer

Abstract: SCC was associated with a significantly higher pCR rate than adenocarcinoma. Recurrence pattern and survival outcomes were significantly different between the 2 histology subtypes in non-pCR patients.

Cited by 72 publications

References 23 publications

Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma

Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma

The Canady Helios Cold Plasma Scalpel Significantly Decreases Viability in Malignant Solid Tumor Cells in a Dose-Dependent Manner

Hazard Curves for Tumor Recurrence and Tumor-Related Death Following Esophagectomy for Esophageal Cancer

Contact Info

Product

Resources

About